Applications

1823 – 177 Lutetium PSMA-617 for prostate specific membrane antigen (PSMA)-positive, taxane-naïve patients with metastatic castrate resistant prostate cancer (mCRPC)

Find out about the service or technology in application 1823 and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input, and the outcome of the application when the MSAC process is complete.

  • Status Pre-assessment
  • Type New application
  • Pre-PASC consultation Open
  • Pre-MSAC consultation Not yet started
  • Outcome Pending

Application details

Applicant

Novartis Pharmaceuticals Australia Pty Limited

Reason for application

New item for funding through the Medicare program

Service or technology in this application

177Lu-PSMA-617 is a type of targeted radiation treatment that attaches to a protein called PSMA, which is often found in high levels in advanced prostate cancer. A PSMA PET scan is used to check PSMA levels and see if a person is suitable for treatment with 177Lu-PSMA-617, which is given through a vein.

Medical condition this application addresses

This application is for treatment of adults with metastatic castration-resistant prostate cancer (mCRPC). These people have cancer that has spread, continues to worsen despite hormone treatment, and tests positive for PSMA. They have been treated with hormone pathway inhibitors but have not received taxane chemotherapy. About 1 in 6 men will be diagnosed with prostate cancer during their lifetime, making it the most common cancer in Australian men. Most men are diagnosed early, but some develop mCRPC despite treatment. This stage of disease usually has the poorest outlook, with studies showing average survival of around 3 to 4 years.

Consultation survey and deadlines

We welcome input from everyone. We are especially keen to hear from those with lived experience of the health condition, service or technology the application is addressing.   

Before providing your input, please read our Privacy Notice for MSAC consultation input to ensure you are comfortable with how we will use your input.  

The following consultation deadlines apply:

  • Pre-PASC consultation deadline: Friday 10 July 2026 11:59pm AEST
  • Pre-MSAC consultation deadline: To be confirmed

For other ways to provide input, see how to have your say.

Find out more about consultation.

Meetings to consider this application

This application will be considered at the following meetings:

  • PASC meeting: 13 to 14 August 2026
  • ESC meeting: To be confirmed
  • MSAC meeting: To be confirmed

Find out more about our meetings.

Outcome details

The outcome of this application is pending.

More information

Find out more about: